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Background. Fibronectin type III domain-containing (FNDC) proteins fulﬁll manifold functions in tissue development and
regulation of cellular metabolism. FNDC4 was described as anti-inﬂammatory factor, upregulated in inﬂammatory bowel disease
(IBD). FNDC signaling includes direct cell-cell interaction as well as release of bioactive peptides, like shown for FNDC4 or
FNDC5. The G-protein-coupled receptor 116 (GPR116) was found as a putative FNDC4 receptor. We here aim to
comprehensively analyze the mRNA expression of FNDC1, FNDC3A, FNDC3B, FNDC4, FNDC5, and GPR116 in nonaﬀected
and aﬀected mucosal samples of patients with IBD or colorectal cancer (CRC). Methods. Mucosa samples were obtained from 30
patients undergoing diagnostic colonoscopy or from surgical resection of IBD or CRC. Gene expression was determined by
quantitative real-time PCR. In addition, FNDC expression data from publicly available Gene Expression Omnibus (GEO) data
sets (GDS4296, GDS4515, and GDS5232) were analyzed. Results. Basal mucosal expression revealed higher expression of
FNDC3A and FNDC5 in the ileum compared to colonic segments. FNDC1 and FNDC4 were signiﬁcantly upregulated in IBD.
None of the investigated FNDCs was diﬀerentially expressed in CRC, just FNDC3A trended to be upregulated. The GEO data set
analysis revealed signiﬁcantly downregulated FNDC4 and upregulated GPR116 in microsatellite unstable (MSI) CRCs. The
expression of FNDCs and GPR116 was independent of age and sex. Conclusions. FNDC1 and FNDC4 may play a relevant role in
the pathobiology of IBD, but none of the investigated FNDCs is regulated in CRC. GPR116 may be upregulated in advanced or
MSI CRC. Further studies should validate the altered FNDC expression results on protein levels and examine the corresponding
functional consequences.
1. Introduction
Fibronectin type III domain-containing 4 (FNDC4) was
recently found by Bosma et al. as a novel anti-inﬂammatory
factor, upregulated in human and murine intestinal inﬂam-
mation and with therapeutic potential in inﬂammatory
bowel disease (IBD) [1]. FNDC4 is one of in total eight so
far identiﬁed members of the FNDC protein family in
humans [2]. The FNDC proteins are characterized by at least
one ﬁbronectin type III domain (FN3). Their various func-
tions include tissue development and cell adhesion, migra-
tion, and proliferation. Several studies showed that FNDCs
are regulated by microRNAs [3–5]. Additionally, other
mechanisms such as FNDC4 regulation by TGF-β and
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corticoid receptor involvement for FNDC5 expression were
also described [1, 6]. General expression analyses and func-
tional reports exist for FNDC1, FNDC3A, FNDC3B, FNDC4,
and FNDC5. FNDC1 activates G-protein signaling 8 (AGS8)
and was previous described as a regulator of cardiovascular
functions. In particular, FNDC1 plays a role in VEGF-medi-
ated angiogenesis and is required for hypoxia-induced
apoptosis in cardiomyocytes [7, 8]. Quantitative trait loci
(QTL) analysis found protein-altering mutations in FNDC1
that are associated with arterial hypertension [9]. On the
other hand, FNDC1 expression correlates with aggressive
prostate cancer [3]. FNDC3A contributes to the synthesis of
extracellular matrix in odontoblasts and to spermatogenesis
[10, 11]. It interacts with the human leukocyte antigen
DRB1 in the pathogenesis of rheumatoid arthritis and expres-
sion analyses in colonic tissue showed that FNDC3A is upreg-
ulated in sporadic CRC [12, 13]. FNDC3B promotes
epithelial-to-mesenchymal transition and activates multiple
cancer pathways, for example, in squamous cell carcinoma,
acute promyelocytic leukemia, and hepatocellular carcinoma
[14–17]. To date, FNDC5 is the most extensively studied
FNDC, mainly because it is the launch vehicle of the peptide
hormone irisin, which was proposed to facilitate the conver-
sion of white adipose tissue into beige adipose tissue [18].
Yet, this concept is not completely understood and contro-
versially discussed [19]. These mainly recently published data
on FNDCs reveal a variety of functions in healthy and dis-
eased conditions in multiple organs and testify upcoming
interest in structured analysis of these proteins.
Similar to FNDC5, FNDC4 is cleaved and releases a
functional active peptide [1]. The exact receptor or binding
partner to facilitate downstream signaling is, so far, not
fully understood. However, Georgiadi et al. revealed in an
in vitro binding study the orphan G-protein-coupled recep-
tor 116 (GPR116) as a putative functional FNDC4 receptor
candidate [20]. GPR116 is expressed in various tissues,
including lung, kidney, or fat, and it has been described
to be overexpressed in metastatic colorectal cancer (CRC)
or breast cancer [21, 22].
The expression of FNDCs and GPR116 in human IBD
and CRC has not been investigated orderly. Therefore, this
study is aimed at exploring the expression of FNDC1,
FNDC3A, FNDC3B, FNDC4, FNDC5, and GPR116 in nonaf-
fected and aﬀected mucosa samples of patients with IBD or
CRC. Information about the regulation of the basal gene
expression could be helpful for a better understanding of
pathophysiological disease mechanisms and for the identiﬁ-
cation of potential therapeutic targets.
2. Materials and Methods
2.1. Human Sample. IBD samples were collected at the
Medical Department, Division of Hepatology and Gastro-
enterology, Campus Virchow-Klinikum at Charité–Univer-
sitätsmedizin Berlin, or at Praxis Dr. med. Wolfgang Spitz
from patients with ulcerative colitis (UC) or Crohn’s disease
(CD) undergoing routine diagnostic colonoscopy. CRC sam-
ples were collected at the Department of Surgery at Char-
ité–Universitätsmedizin Berlin from patients undergoing
surgical resection. Samples that showed no pathological
signs macroscopically or histologically were included as
controls (nonaﬀected samples). Collected samples were
immediately frozen in liquid nitrogen and stored at -80°
until further use. The study was approved by the local
ethics committee (registry number EA2/021/16) and con-
ducted in accordance with the Declaration of Helsinki.
Written informed consent was obtained from each patient
before enrolment.
2.2. Patients’ Characteristics. In this study, 20 IBD patients,
10 UC patients, and 10 CD patients participated. In total,
44 double-bite mucosal biopsies (two bites per pass of the
forceps [23]) covering the proximal-distal axis were obtained
by experienced gastroenterologists. Samples were allocated
histologically into three groups: IBD nonaﬀected, UC
aﬀected, and CD aﬀected (Table 1). Patients’ clinical disease
activity was assessed using two common scores: the Mayo
Score for ulcerative colitis and the Harvey-Bradshaw Index
for Crohn’s disease. The Mayo Score was described by
Schroeder et al. [24] in 1987 and composites four categories,
including stool frequency, rectal bleeding, mucosal appear-
ance at endoscopy, and physician rating of disease activity,
with a maximum score of 12. The Harvey-Bradshaw Index
was introduced in 1980 as a simpler version of the Crohn’s
disease activity index (CDAI) containing only clinical
parameters, including general well-being, abdominal pain,
number of liquid stools per day, abdominal mass, and com-
plications [25]. The sum of items categorizes the patients into
remission (<5), mild disease (5-7), moderate disease (8-16),
and severe disease (>16). Additionally, the current medica-
tion and basic laboratory ﬁndings of study patients were
recorded (Table 1). The 8 patients in the UC aﬀected group
included 7 males and 1 female, with a median age of 39
(26-54) years. These patients were most diagnosed with pan-
colitis (5/8) and a mild disease activity (7/8) according to the
Mayo Score. The 8 patients in the CD aﬀected group included
3 males and 5 females, with a median age of 32 (28-60) years.
50% of these patients were in clinical remission according to
the Harvey-Bradshaw Index; they mainly displayed ileocolo-
nic disease activity. At the time of enrolment, all patients
received anti-inﬂammatory medication.
In addition, 10 patients with CRC enrolled in this study;
one of those patients participated with two synchronous
CRCs. Expression in aﬀected samples was compared with
nonaﬀected samples taken from adjacent mucosa of each
patient. All CRC patients were men and their median age
was 64.5 years. 6/11 carcinoma samples were originated in
the rectum. 8/10 patients did not receive any neoadjuvant
therapy. CRCs were mainly staged as UICC stage I or II
and histologically moderate diﬀerentiated (G2). 8/11 CRC
were microsatellite stable; two pathological analyses did not
reveal information about microsatellite stability. Clinical
data, histological analysis, and laboratory ﬁndings of CRC
subjects are listed in Table 2.
2.3. Bioinformatic Analysis of Gene Expression Proﬁles. Data
sets containing array-based gene expression proﬁle data
(normalized expression values) were retrieved from the Gene
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Expression Omnibus (GEO) platform. The normalized
expression values (given in arbitrary units) were analyzed
for diﬀerential gene expression of FNDCs and GPR116 in
CRC cell lines (GDS4296) and microsatellite unstable
carcinoma (MSI CRCs) (GDS4515) as well as in early- vs.
late-onset carcinoma in males and female (GDS5232), using
one-way ANOVA for multiple comparison test and t-tests
for comparing two groups.
Table 1: IBD patients’ characteristics.
IBD nonaﬀected UC aﬀected CD aﬀected
Number of subjects 11 (4 CU, 7 CD) 8 8
Age, median years (range) 45 (27-60) 39 (26-54) 32 (28-60)
Age at ﬁrst diagnosis (mean ± SD) 30 8 ± 7 2 29 4 ± 6 5 27 5 ± 6 9
Sex (male/female) 6/5 7/1 3/5
Localization
Ileum 5 0 4
Ascending colon 5 1 0
Transverse colon 6 4 1
Descending colon 5 1 1
Sigmoid colon 1 3 1
Rectum 4 1 1
Mayo Score
No activity (0-1) 4 0 NA
Mild disease (2-5) 0 7 NA
Moderate/severe disease (≥6) 0 1 NA
Harvey-Bradshaw Index
Remission (<5) 4 NA 4
Mild disease (5-7) 3 NA 3
Moderate disease (8-16) 0 NA 1
Severe disease (>16) 0 NA 0
Montreal classiﬁcation
E1, E2, E3 0/1/3 0/3/5 NA
A1, A2, A3 0/6/1 NA 0/7/1
L1, L2, L3, L4 1/3/3/0 NA 1/4/3/0
B1, B2, B3, B3p 1/4/1/1 NA 1/4/1/2
Medication
No 0 0 0
5-ASA 2 5 1
Corticosteroids 2 2 2
Immunosuppressives 2 2 0
Biologicals 9 3 6
Small molecule drugs 0 0 1
As combination 4 3 2
Laboratory ﬁndings (mean ± SD)
Erythrocytes (1012/L) 4 5 ± 0 46 4 7 ± 0 64 4 6 ± 0 38
Leukocytes (109/L) 8 56 ± 2 82 7 68 ± 2 39 9 61 ± 3 87
Thrombocytes (109/L) 292 8 ± 123 314 7 ± 99 1 344 9 ± 81 9
Hemoglobin (g/dL) 13 3 ± 0 7 12 8 ± 2 13 5 ± 1
CRP (mg/L) 2 1 ± 3 8 7 5 ± 9 9 6 5 ± 9 9
Sodium (mmol/L) 141 2 ± 2 1 140 9 ± 1 2 140 3 ± 2 3
Potassium (mmol/L) 4 01 ± 0 2 4 14 ± 0 3 3 97 ± 0 14
Each column lists characteristics for all patients contributing with samples to the corresponding sample group. Abbreviations: E1: ulcerative proctitis; E2: left-
sided UC; E3: pancolitis; A1: below 16 y; A2: between 17 and 40 y; A3: above 40 y; L1: ileal; L2: colonic; L3: ileocolonic; L4: isolated upper disease; B1:
nonstricturing, nonpenetrating; B2: stricturing; B3: penetrating; B3p: perianal disease; 5-ASA: 5-aminosalicylic acid; CRP: C-reactive protein.
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2.4. Quantitative Real-Time RT-PCR. RNA was extracted
using the PureLink™ RNA Mini Kit (Invitrogen, CA, USA)
according to manufacturer’s protocol using a rotating
homogenizer (Retsch MM400, Haan, Germany). Quality
and quantity controls were performed for each extract using
the NanoDrop™ 2000 Spectrophotometer (Thermo Scien-
tiﬁc, DE, USA). Immediately after RNA extraction, cDNA
synthesis was performed using the High-Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, CA, USA)
following manufacturer’s instructions. The cDNA was stored
at -20° until use. For qRT-PCR reactions, the GoTaq® qPCR
Master Mix (Promega, WI, USA) was used and a 7500 Real-
Time PCR Cycler System (Applied Biosystems, CA, USA) to
run the PCRs. Primer sequences are listed in Table 3. The
inﬂammatory markers chemokine (C-C motif) ligand 2
(CCL2), interleukin 4 (IL-4), and tumor necrosis factor
(TNF) have been shown to be upregulated in mucosal biop-
sies of patients with inﬂammatory bowel disease [26–28]
and were therefore measured additionally to validate inﬂam-
matory processes in our mucosa samples. Cycling conditions
were as follows: initial denaturation for 10min at 95°C,
followed by 40 cycles of denaturation at 95°C for 15 s and
annealing/extension at 60°C for 60 s. Melt curve analysis
was carried out from 60 to 95°C with a temperature tran-
sition rate of 0.1°C/s. The expression of FNDCs and
inﬂammatory markers was, if not otherwise indicated, nor-
malized to the housekeeping genes actin-beta (ACTB) and
TATA box-binding protein (TBP) and expressed as fold
change to the expression in nonaﬀected samples, using
the 2−ΔΔCt equation [29]. Ampliﬁed PCR product lengths
were qualitatively analyzed by electrophoresis on 3% aga-
rose gels containing ethidium bromide to determine pre-
dicted product length.
2.5. Statistical Analysis. All statistical analyses were per-
formed using the Statistical Package for the Social Sciences
(SPSS, version 25.0, IBM, NY, USA) or GraphPad Prism 5.0
(GraphPad Software, CA, USA). The results are expressed
as mean ± SEM. Statistical comparisons between two groups
were performed using t-tests. Grubbs’ test was performed to
identify outliers. Statistical signiﬁcant diﬀerences were
deﬁned as p < 0 05(∗), p < 0 01(∗∗), and p < 0 001(∗∗∗).
3. Results
3.1. Gene Expression of FNDCs and GPR116 in Nonaﬀected
Mucosal Samples along the Proximal-Distal Axis. Basal FNDC
expression was assessed in nonaﬀected samples along the
proximal-distal axis starting from the ileum to the rectum
(Figure 1(a)). As all samples in this analysis were nonaﬀected,
the expression was calculated in fold change to expression
of the ileum. Signiﬁcant expression diﬀerences in nonaf-
fected mucosal samples along the proximal-distal axis were
found for FNDC3A and FNDC5; both were expressed at a
higher level in the ileum compared to colonic segments
(p < 0 0001 for FNDC3A, p = 0 0118 for FNDC5). No sta-
tistical expression diﬀerences along the proximal-distal axis
were found for FNDC1, FNDC3B, FNDC4, and GPR116,
respectively. For qRT-PCR result veriﬁcation, the actual
Table 2: CRC patients’ characteristics.
Number of subjects 10
Age, median years (range) 64.5 (50-80)
Age at ﬁrst diagnosis (mean ± SD) 62 3 ± 9 9
Sex (male/female) 10/0
Localization
Ileum 0
Caecum 0
Ascending colon 1
Transverse colon 1
Descending colon 1
Sigmoid colon 2
Rectum 6
Neoadjuvant therapy
None 8
Grade 1 (Dworak) 1
Grade 2 (Dworak) 1
UICC stage
NA 1
Stage I 4
Stage II 3
Stage III 1
Stage IV 1
Histological diﬀerentiation
NA 1
G1 0
G2 8
G3 1
G4 0
Microsatellite stability
NA 2
MSS 8
MSI 0
KRAS mutation 1
BRAF mutation 1
Positive family history 5
Smokers (pack-years, range) 7 (28, 10-75)
Daily alcohol 5
Laboratory ﬁndings (mean ± SD)
Erythrocytes (1012/L) 4 7 ± 0 46
Leukocytes (109/L) 8 21 ± 3 76
Thrombocytes (109/L) 251 1 ± 94 6
Hemoglobin (g/dL) 13 4 ± 2 1
Sodium (mmol/L) 139 6 ± 4 3
Potassium (mmol/L) 4 36 ± 0 55
CEA (μg/L) 7 9 ± 16 7
CA 19-9 (U/mL) 180 5 ± 392 4
The column lists characteristics for all patients with CRC. Abbreviations:
UICC: Union for International Cancer Control; NA: not available; G1: well
diﬀerentiated; G2: moderately diﬀerentiated; G3: poorly diﬀerentiated; G4:
undiﬀerentiated; CEA: carcinoembryonic antigen; CA 19-9: carbohydrate
antigen 19-9.
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amplicon sizeswere determined by ethidiumbromide gel elec-
trophoresis and compared to predicted lengths (Figure 1(b)).
3.2. Gene Expression of FNDCs and GPR116 in Nonaﬀected
Mucosal Samples of IBD vs. CRC Patients. No diﬀerences
were found for the expression of FNDC1 (p = 0 1760),
FNDC4 (p = 0 4374), or FNDC5 (p = 0 6781) in nonaﬀected
mucosal samples of IBD compared to the expression in non-
aﬀected mucosal samples of CRC patients, respectively
(Figure 1(c)). Signiﬁcantly higher levels of FNDC3A and
FNDC3B were found in nonaﬀected samples of IBD patients,
as compared to nonaﬀected samples of CRC patients.
GPR116 was expressed at higher levels in CRC samples, as
compared to nonaﬀected samples of IBD patients.
3.3. FNDC1 and FNDC4 Are Signiﬁcantly Upregulated in
Inﬂamed Colonic Mucosal Samples. Mucosal samples of
IBD patients were collected from actively inﬂamed and non-
aﬀected sites. In macroscopically and histologically inﬂamed
samples, FNDC1 and FNDC4 were signiﬁcantly upregulated,
compared to all nonaﬀected samples used previously for
Figure 1(a) (FNDC1 5.5-fold, p = 0 0244; FNDC4 13.8-fold,
p = 0 0149). FNDC3A, FNDC3B, FNDC5, and GPR116
showed no diﬀerences between inﬂamed and nonaﬀected
samples (Figure 2(a)). Focusing on the gene expression of
FNDC4 and GPR116, FNDC4 is upregulated in active UC
(7-fold increase, p < 0 001) as well as in active CD (22-fold
increase, p = 0 0462) (Figures 2(b) and 2(c)). A more pro-
nounced inﬂammatory reaction was observed in UC sam-
ples, as reﬂected by the expressions of CCL2, IL-4, and
TNF, that were only signiﬁcantly regulated in UC samples
(p < 0 01) and not in CD samples (Figures 2(b) and 2(c)).
GPR116 was not speciﬁcally regulated in UC or CD
(p = 0 192 in UC, p = 0 1835 in CD), although it tended
to increase.
3.4. Unchanged FNDCs and GPR116 Expression in CRC. CRC
samples were compared to surrounding nonaﬀected samples
that were previously used in the calculation for Figure 1(c)
(n = 8-10); however, none of the investigated genes was
diﬀerentially expressed (Figure 3). FNDC3A showed the
strongest tendency of increasing expression in CRC, yet not
reaching statistical signiﬁcance (p = 0 097).
3.5. FNDCs and GPR116 Expression in GEO Data Sets. Pub-
licly available data sets of the GEO database were analyzed
to complement our ﬁndings with previous comparable stud-
ies. First, microarray expression of FNDCs in seven human
colonic tumor cell lines from the NCI-60 panel were obtained
(GDS4296) [30]. All FNDCs were expressed, whereas
FNDC3A displayed the highest expression values (mean
2.4-fold higher) in all cell lines (Figure 4(a)). Signiﬁcant
expression diﬀerences (p < 0 05) in analyzed cell lines were
found regarding FNDC3A and FNDC3B (signiﬁcance bars
are not shown for overview purposes). In the microsatellite-
unstable colorectal cancer data set (GDS4515) of human
MSI CRC samples (n = 34), we analyzed the gene expressions
compared to nonaﬀected colonic mucosa (n = 17) [31]. The
expression data of FNDC3A, FNDC3B, FNDC4, and
GPR116 were available and showed a small but signiﬁcant
downregulation of FNDC4 in MSI CRCs (p = 0 047,
Figure 4(b)), while FNDC3A (p = 0 055) and FNDC3B
(p = 0 127) remained unchanged. GPR116 was signiﬁcantly
upregulated (p = 0 014). To test for possible confounding by
age or sex, we analyzed expression data in early- and late-
onset CRCs in females (n = 21) and males (n = 25), diagnosed
at an age of 28-53 years (n = 27) or 69-87 years (n = 19)
(GDS5232) [32]. Data were available for FNDC3A, FNDC4,
and GPR116, which showed neither age- (p = 0 548, p =
0 906, and p = 0 160) nor sex-dependent diﬀerences
(p = 0 438, p = 0 629, and p = 0 547).
4. Discussion
In this exploratory study, we investigated the gene expression
of FNDC1, FNDC3A, FNDC3B, FNDC4, FNDC5, and
GPR116 in IBD and CRC. Our main mRNA expression
results as well as the proposed gene function are listed in
Table 4. First, basal gene expression was analyzed in the
proximal-distal row showing similar expressions for FNDC1,
FNDC3B, FNDC4, and GPR116, whereas FNDC3A and
FNDC5 were dominantly expressed in the ileum. The
Table 3: Primer sequences used for qRT-PCR (5′-3′).
Gene product Gene accession number Forward primer sequence Reverse primer sequence Product size (bp)
FNDC1 NM_032532 GAG CCT TCG ACC ACT GCT AC ATT TCA TCC AGG CTG TCC AC 200
FNDC3A NM_001079673 GCA CAA GTG AAT TGG GAG GT CAC AAC ACT CAG AGC CTG GA 183
FNDC3B NM_022763 AGT CTC CCT GTT CGC ACA CT CTC TGG GCC ATG GTA CAC TT 195
FNDC4 NM_022823 GCA CTT CCG AAC TCT CAA GG TGG GAT TGT TGT TGG AGT CA 212
FNDC5 NM_153756 CAT CTC CCA GCA GAA GAA GG GGT TCC TCC CCA TCT CTT TC 245
GPR116 NM_015234 GGA AGC TGT GGT GTG GAA AT CAG GCG ATA GAA CAG CAT GA 247
CCL2 NM_002982 CCC CAG TCA CCT GCT GTT AT TGG AAT CCT GAA CCC ACT TC 171
IL-4 NM_000589 TGA ACA GCC TCA CAG AGC AG TCA GGA ATC GGA TCA GCT GC 210
TNF NM_000594 CAG AGG GCC TGT ACC TCA TC GGA AGA CCC CTC CCA GAT AG 219
ACTB NM_001101 GGA CTT CGA GCA AGA GAT GG AGC ACT GTG TTG GCG TAC AG 234
TBP NM_003194 TAT AAT CCC AAG CGG TTT GC GCT GGA AAA CCC AAC TTC TG 170
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unchanged expression for FNDC4 has been also previously
reported [1]. The biological relevance of variable regional
expression pattern still remains unknown.
Concerning IBD, it was reported that FNDC4 is upreg-
ulated in the mucosa and acts as an anti-inﬂammatory
factor via the downregulation of proinﬂammatory genes
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Figure 1: FNDCs and GPR116 expression in nonaﬀected human mucosal samples. FNDC1, FNDC3A, FNDC3B, FNDC4, FNDC5, and
GPR116 in nonaﬀected mucosal samples along the proximal-distal axis (n = 4-5) (a). Representative agarose gels of qRT-PCR products,
including the expected amplicon lengths for each gene (b). Quantiﬁcation of FNDC1, FNDC3A, FNDC3B, FNDC4, FNDC5, and GPR116
in nonaﬀected samples of patients with IBD (n = 22) and CRC (n = 7-10) (c). Data are expressed relative to the expression in nonaﬀected
IBD samples and normalized to the housekeeping genes ACTB and TBP. ∗p < 0 05, ∗∗p < 0 01, and ∗∗∗p < 0 001.
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and phagocytosis [1]. Our data conﬁrmed the upregulation
of FNDC4 in UC and CD samples. Moreover, we found
FNDC1, as a second gene of the FNDC family, upregulated
in IBD. This might suggest a functional role of FNDC1 in
IBD, which was until now foremost known for its patho-
logical role in cardiocirculatory disorders and prostate cancer
[3, 7–9]. The upregulation of FNDC1 and FNDC4 expression
and the subsequent translation might aﬀect intracellular or
cell-cell signaling. So far, several FNDC receptor candidates
have been described in diﬀerent organs or cells. It has been
described that FNDC1 regulates the androgen receptor in
prostate cancer [3]. Furthermore, FNDC1 forms complexes
with G protein beta gamma subunit and connexins in cardi-
omyocytes and regulates several VEGF receptors in endothe-
lial cells [7, 8, 33]. FNDC4 has been shown to suppress
inﬂammation via AMP-activated protein kinase (AMPK)
phosphorylation and heme oxygenase-1 (HO-1) expression
in adipocytes [34]. It has also been shown to inhibit osteo-
clast formation via the suppression of NF-κB and downregu-
lation of CXCL10 [35]. Another FNDC4 receptor candidate
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Figure 2: FNDCs and GPR116 expression in nonaﬀected vs. inﬂamed mucosal samples of IBD patients. Expression levels of FNDC1 and
FNDC4 were signiﬁcantly higher in inﬂamed samples (n = 14) than in nonaﬀected samples (n = 22) of IBD patients (a). FNDC4, GPR116,
CCL2, IL-4, and TNF expression levels in samples of active ulcerative colitis (UC, n = 8) (b) or Crohn’s disease (CD, n = 8) (c), as
compared to nonaﬀected samples. ∗p < 0 05, ∗∗p < 0 01, and ∗∗∗p < 0 001.
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Figure 3: FNDCs and GPR116 expression in colorectal cancer. No
signiﬁcant expression diﬀerences were found in a paired-sample
t-test analysis for any of the investigated genes between cancerous
samples and the surrounding nonaﬀected samples (n = 8-10).
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was supposed by Georgiadi et al., who found that FNDC4
binds to GPR116 [20]. In our analysis, GPR116 was not sig-
niﬁcantly regulated in IBD samples. All our attempts to
establish the detection of FNDC4 protein in mucosal samples
failed, as available antibodies were unable to provide a spe-
ciﬁc staining and were distorted by autoﬂuorescence of IBD
samples (Supplemental ﬁgure (available here)). We discussed
this phenomenon earlier in a separate publication [36].
Therefore, also the exact cellular localization of FNDC4 pro-
tein during inﬂammatory activity remains unknown. One
possible mechanism might involve the activation of macro-
phages [1]. Physiological functions of FNDC5, a close paralog
of FNDC4, include eﬀects on metabolism, e.g., improved glu-
cose metabolism by upregulating uncoupling protein-1
(UCP1) via phosphorylation of the p38 mitogen-activated
protein kinase (p38 MAPK), cardiovascular function, e.g.,
reduced atherosclerosis, skeletal muscle, e.g., myogenesis via
NO-dependent mechanisms, and central nervous system,
e.g., increased hippocampal neurogenesis [37]. Our data con-
ﬁrms the expression proﬁles of FNDC5 in IBD, as shown by
Bosma et al., who found FNDC5 either downregulated or
unchanged in several mouse models of inﬂammation [1].
Concerning CRC, neither FNDCs nor GPR116 was sig-
niﬁcantly regulated in our analysis. So far, no information
about FNDC1 and FNDC4 expression in CRC were avail-
able. As we found no signiﬁcant changes at the transcrip-
tion level, our results suggest that FNDC1 and FNDC4 are
not relevant factors in intestinal dysplasia, although we
cannot exclude a role for (post)translational regulation of
FNDCs. In the microsatellite-unstable colorectal cancer
data set, FNDC4 was small but signiﬁcantly downregu-
lated. That stays in line with a recent Aﬀymetrix microar-
ray analysis, which showed a downregulation of FNDC4 in
a murine metastatic colon adenocarcinoma cell line [31,
38]. These data might point to a suppressed transcription
of FNDC4 in the described CRC pathologies, although
the biological relevance of these small expression diﬀer-
ences remains questionable. For GPR116, we did not ﬁnd
any expression diﬀerences between nonaﬀected mucosa
samples and CRC samples, although it was signiﬁcantly
highly expressed in cancer adjacent mucosa compared to
nonaﬀected mucosa of IBD patients. Yang et al. found a
correlation between highly expressed GPR116 and poor sur-
vival outcome in CRC [21]. In their studies, high GPR116
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Figure 4: Microarray expression values retrieved from the GEO database (data sets GDS4296 and GDS4515). FNDCs and GPR116 are
expressed in several colorectal cancer cell lines from the NCI-60 panel (24) (a). In human MSI colorectal cancer, FNDC4 is signiﬁcantly
downregulated (p = 0 047), whereas GPR116 is upregulated (p = 0 014) (25) (b). ∗p < 0 05.
Table 4: Summary of IBD and CRC analysis and main proposed functions of FNDCs and GPR116.
Gene Regulation in IBD Regulation in CRC Proposed function
FNDC1 Upregulated Unchanged Angiogenesis, apoptosis
FNDC3A Unchanged Trends upregulated Organogenesis
FNDC3B Unchanged Unchanged Cancer pathway activator
FNDC4 Upregulated Unchanged/downregulated∗ Anti-inﬂammatory
FNDC5 Unchanged Unchanged Energy metabolism
GPR116 Unchanged Unchanged/upregulated∗ FNDC4 receptor candidate
∗depending on CRC subtypes.
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expression, semiquantitatively graded by immunohisto-
chemical staining, was found in approximately 50% of their
patients. However, their study population diﬀered from
ours. Yang et al. enrolled 47% stage I-II and 53% stage III-
IV CRCs. 38% of CRCs revealed a poor histological diﬀeren-
tiation, which correlated with high GPR116 expression. In
well/moderate-diﬀerentiated CRCs, the GPR116 expression
was foremost low. We showed low GPR116 expressions in
our predominantly moderate diﬀerentiated CRCs, which is
in line with Yang and colleagues. No information about
microsatellite stability were given by Yang et al., nor were
rectal cancers analyzed. Our analysis of GEO data sets
revealed an upregulated expression of GPR116 in MSI
CRC. MSI is a molecular characteristic in hereditary and
sporadic CRCs that features an antitumoral immune
response and involves good prognosis [39]. Today, CRCs
can be classiﬁed into heterogeneous subtypes, e.g., resulting
from speciﬁc genetic mutations, and therefore, expression
and biomarker studies should provide separate analysis in
subgroups, e.g., MSI CRC. Yet, our data does not allow any
conclusion about a functional relationship between any of
the FNDCs with GPR116. This has to be investigated in fur-
ther studies.
One study showed increased FNDC5 immunoreactivity
in several gastrointestinal tract cancers including CRC [40].
These ﬁndings could not be reproduced in our study. One
main methodical diﬀerence between the studies is the
FNDC5 analysis on the protein level, while we analyzed
mRNA expression. Due to the common lack of congruency
between RNA expression and protein abundance, the eﬀects
seen on the mRNA levels do not necessarily translate into
protein abundance [41].
IBD patients are at high risk to develop CRC in the
course of the disease, caused by the continuous tissue
inﬂammation, repair, and remodeling. The CRC risk rises
up to 2.4-fold for patients with UC and up to 1.9-fold for
patients with CD [42, 43]. Therefore, FNDC expression in
the course of CRC development based on IBD could help
to better understand their importance during the disease
progression. However, in this study, only patients with spo-
radic CRC participated. Just little is known about the role of
FNDCs in the pathogenesis of CRC, especially if it is based
on IBD. Shivakumar et al. analyzed the copy number varia-
tions of FNDC3A and found it highly ampliﬁed in sporadic
CRC but not in UC-associated neoplasia [13]. In contrast,
positive immunostaining for FNDC3A was found in patients
with an extensive course of UC, especially with neoplastic
changes. In our CRC samples, FNDC3A was close to signif-
icance (p = 0 097) for higher expression in CRC compared to
nonaﬀected surrounding mucosa. That might have been lim-
ited due to the relatively low sample number. Further studies
should solidify the expression of FNDC3A as well as its func-
tional implications in CRC on larger study cohorts compar-
ing homogenous pathologies. FNDC3B, the second member
of the FNDC3 subfamily, shares 50% amino acid identity
with FNDC3A. It is known that FNDC3B is highly ampliﬁed
in esophageal, lung, ovarian, and breast cancer and it has
been associated with the activation of several cancer path-
ways including PI3-kinase/Akt, Rb1, and TGF-β signaling
[14]. Recently, Chen et al. propose FNDC3B as potential bio-
marker for lymph node metastatic CRC [44]. Unfortunately,
we could not conﬁrm this, since 8/11 of our CRC specimen
were lymph node negative. We found FNDC3B expression
unchanged in IBD and CRC.
5. Conclusions
This exploratory gene expression study provides ﬁrst insights
of ﬁbronectin type III domain-containing proteins in IBD
and CRC. FNDC1 and FNDC4 are upregulated in IBD, while
no signiﬁcant changes for FNDCs or GPR116 were found in
CRC. The diagnostic potential and pathomechanistic contri-
bution of FNDCs are most likely to be limited to IBD but not
CRC development. Still, GPR116 might be upregulated in
advanced or MSI CRC. Further research is required to val-
idate expression diﬀerences on the protein level and to
elucidate functional consequences, including FNDC recep-
tor interactions as well as signaling mechanisms on the
molecular level.
Data Availability
All data used to support the ﬁndings of this study are avail-
able from the corresponding author upon request.
Conflicts of Interest
The authors declare that there is no conﬂict of interest
regarding the publication of this paper.
Authors’ Contributions
Tilo Wuensch and Jonas Wizenty share ﬁrst authorship.
Acknowledgments
The authors acknowledge the support from the German
Research Foundation (DFG) and the Open Access Publica-
tion Fund of Charité – Universitätsmedizin Berlin.
Supplementary Materials
Supplemental ﬁgure: immunoﬂuorescence staining and
autoﬂuorescence of inﬂamed intestinal tissue. (a) A sube-
pithelial cellular IF label is visible with the use of 1st anti-
body: Anti-FNDC4 (HPA015804, dilution 1 : 50, Sigma-
Aldrich) and 2nd antibody: Goat Anti-Rabbit IgG H&L
(Alexa Fluor® 594) (ab150080, dilution 1 : 200, Abcam).
Colonic crypts are labeled by Cadherin-17 antibody
(MAB1032, R&D Systems) with 2nd antibody Goat Anti-
Mouse IgG FITC (F0257, dilution 1 : 250, Sigma-Aldrich).
DAPI was used for counterstaining. (b) The subepithelial
cellular label also appears in a labeling control without
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antibodies after an excitation with 594 nm and is therefore
autoﬂuorescence. (Supplementary Materials)
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